IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.8257
-0.0346 (-4.02%)
At close: Oct 16, 2025, 4:00 PM EDT
0.8200
-0.0057 (-0.69%)
Pre-market: Oct 17, 2025, 6:29 AM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $525.00K in the quarter ending June 30, 2025, a decrease of -48.07%. This brings the company's revenue in the last twelve months to $2.79M, down -16.46% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$2.79M
Revenue Growth
-16.46%
P/S Ratio
16.60
Revenue / Employee
$42,227
Employees
66
Market Cap
56.93M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
Dec 31, 2020 | 3.87M | 2.21M | 132.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ICCM News
- 3 days ago - IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances - PRNewsWire
- 7 days ago - IceCure Medical to Attend the 2025 Maxim Growth Summit - PRNewsWire
- 10 days ago - IceCure Medical Ltd - Special Call - Seeking Alpha
- 13 days ago - IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - PRNewsWire
- 13 days ago - IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - PRNewsWire
- 16 days ago - IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented - PRNewsWire
- 24 days ago - IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented - PRNewsWire
- 4 weeks ago - IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes - PRNewsWire